Related Experiment Videos

[Clinical study on effect of ganneng dripping pill in treating chronic hepatitis B]

Li Li1, Hai-long Yuan, Qin Wu

  • 1The Seventh Department of Infection, 302 Hosipital of PLA, Beijing.

Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi = Chinese Journal of Integrated Traditional and Western Medicine
|October 25, 2006
PubMed

Insights

Ganneng Dripping Pill (GDP) shows short-term efficacy in treating chronic hepatitis B by inhibiting HBV replication and improving liver function and symptoms. This traditional Chinese medicine offers a potential therapeutic option for chronic hepatitis B patients.

Area of Science:

  • Hepatology
  • Virology
  • Traditional Chinese Medicine

Context:

  • Chronic hepatitis B (CHB) remains a significant global health concern.
  • Effective antiviral therapies are crucial for managing CHB and preventing complications.
  • Ganneng Dripping Pill (GDP) is a traditional Chinese medicine investigated for its therapeutic potential.

Purpose:

  • To evaluate the antiviral efficacy of Ganneng Dripping Pill (GDP) in patients with chronic hepatitis B.
  • To compare the effects of GDP with lamivudine, a standard antiviral treatment.

Summary:

  • A randomized controlled trial compared GDP with lamivudine in 84 CHB patients over 6 months.
  • While both treatments showed similar rates for HBV-DNA and HBeAg negativity, GDP significantly improved AST normalization and clinical symptoms.
  • GDP demonstrated a favorable short-term effect, inhibiting HBV replication and improving liver function and patient well-being.

Impact:

  • GDP offers a promising therapeutic option for chronic hepatitis B, particularly in symptom management and liver function improvement.
  • This study contributes to understanding the role of traditional Chinese medicine in managing viral hepatitis.
  • Further research may explore long-term efficacy and safety profiles of GDP in CHB treatment.
Abstract

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...